{"altmetric_id":1607677,"counts":{"readers":{"mendeley":6,"citeulike":0,"connotea":0},"total":{"posts_count":3},"twitter":{"unique_users_count":2,"unique_users":["CancerCureNow","SWCINFOFEED"],"posts_count":3}},"selected_quotes":["Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776)","Bevacizumab in Combination with Sorafenib for Treatment o.. -"],"citation":{"abstract":"We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect. We also investigated whether VEGF, VEGFR2 and hypoxia-inducible factor-1\u03b1 single-nucleotide polymorphisms (SNP), circulating biomarkers of angiogenesis, and MRI markers such as apparent diffusion coefficient (ADC) are correlated with treatment efficacy and\/or toxicity.","abstract_source":"pubmed","altmetric_jid":"4f6fa6113cf058f610006efa","authors":["Evanthia Galanis","S. Keith Anderson","Jacqueline M. Lafky","Joon Uhm","Caterina Giannini","Shaji K. Kumar","Teresa Kimlinger","Donald W. Northfelt","Patrick J. Flynn","Kurt Jaeckle","Timothy J. Kaufmann","Jan C. Buckner","Galanis E","Anderson SK","Lafky JM","Uhm J","Giannini C","Kumar SK","Kimlinger T","Northfelt DW","Flynn PJ","Jaeckle K","Kaufmann TJ","Buckner JC"],"doi":"10.1158\/1078-0432.ccr-13-0708","endpage":"4823","first_seen_on":"2013-07-06T10:53:52+00:00","funders":["nci"],"issns":["1557-3265","1078-0432"],"issue":"17","journal":"Clinical Cancer Research","last_mentioned_on":1378217752,"links":["http:\/\/clincancerres.aacrjournals.org\/content\/early\/2013\/07\/04\/1078-0432.CCR-13-0708.abstract.html?papetoc"],"pdf_url":"http:\/\/clincancerres.aacrjournals.org\/content\/early\/2013\/07\/04\/1078-0432.CCR-13-0708.full.pdf","pmid":"23833308","pubdate":"2013-01-01T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"startpage":"4816","title":"Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial","type":"article","volume":"19","mendeley_url":"http:\/\/www.mendeley.com\/research\/phase-ii-study-bevacizumab-combination-sorafenib-recurrent-glioblastoma-n0776-north-central-cancer-t"},"altmetric_score":{"score":0.75,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.75},"context_for_score":{"all":{"total_number_of_other_articles":4835876,"mean":5.7704781864728,"rank":3232152,"this_scored_higher_than_pct":29,"this_scored_higher_than":1411529,"rank_type":"exact","sample_size":4835876,"percentile":29},"similar_age_3m":{"total_number_of_other_articles":91657,"mean":7.6431094745571,"rank":58749,"this_scored_higher_than_pct":31,"this_scored_higher_than":29068,"rank_type":"exact","sample_size":91657,"percentile":31},"this_journal":{"total_number_of_other_articles":4127,"mean":4.0520698012603,"rank":3004,"this_scored_higher_than_pct":20,"this_scored_higher_than":857,"rank_type":"exact","sample_size":4127,"percentile":20},"similar_age_this_journal_3m":{"total_number_of_other_articles":2,"mean":1.5,"rank":2,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":2,"percentile":1}}},"demographics":{"poster_types":{"member_of_the_public":2},"users":{"twitter":{"cohorts":{"Members of the public":2}},"mendeley":{"by_status":{"Professor > Associate Professor":1,"Researcher":1,"Student  > Ph. D. Student":1,"Other":2,"Student  > Bachelor":1},"by_discipline":{"Medicine and Dentistry":1,"Agricultural and Biological Sciences":1,"Biochemistry, Genetics and Molecular Biology":4}}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/CancerCureNow\/statuses\/353466786886324224","license":"public","citation_ids":[1607677],"posted_on":"2013-07-06T10:53:43+00:00","author":{"name":"Cure Cancer Now","url":"http:\/\/cancercure-d.blogspot.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/1128872809\/Hep_G2_Lab_test_normal.jpg","description":"Pure science is what it is taking to defeat cancer. Follow us to be a part of history in the making. Receive only the best information here.","id_on_source":"CancerCureNow","tweeter_id":"193691326","geo":{"lt":null,"ln":null},"followers":8359},"tweet_id":"353466786886324224"},{"url":"http:\/\/twitter.com\/CancerCureNow\/statuses\/369800163725828098","license":"public","citation_ids":[1607677],"posted_on":"2013-08-20T12:36:44+00:00","author":{"name":"Cure Cancer Now","url":"http:\/\/cancercure-d.blogspot.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/1128872809\/Hep_G2_Lab_test_normal.jpg","description":"Pure science is what it is taking to defeat cancer. Follow us to be a part of history in the making. Receive only the best information here.","id_on_source":"CancerCureNow","tweeter_id":"193691326","geo":{"lt":null,"ln":null},"followers":8359},"tweet_id":"369800163725828098"},{"url":"http:\/\/twitter.com\/SWCINFOFEED\/statuses\/374898542784954368","license":"datasift","rt":["_feedspot"],"citation_ids":[1607677],"posted_on":"2013-09-03T14:15:52+00:00","author":{"name":"HEYRUBE","image":"http:\/\/pbs.twimg.com\/profile_images\/378800000698198333\/c1e28c7ca1142506ca13936c9172acc4_normal.jpeg","description":"I WILL NOT HURT OR HARM YOU. JUST GIVE ME BACK MY MORAL COMPASS, LANCE.  IT WAS A GOOD COMPASS.. & I LIKE IT. YOU KNOW HOW HARD IT IS TO FIND A COMPASS YOU LIKE","id_on_source":"SWCINFOFEED","tweeter_id":"1717428164","followers":62},"tweet_id":"374898542784954368"}]}}